The pharma and biotech industries have reached significant R&D milestones in the past decade, including the broad adoption of immunotherapy and the advent of gene therapies. Despite these breakthroughs, the productivity of research and development efforts among large pharma/biotech remains low. As novel methods of development become more commonplace and the areas of focus shift from larger disease areas to more niche diseases, pharma companies will need to expand on existing capabilities across the product lifecycle. In this paper Emre Vural, Kishore Gangangari, and Joanna Lee look at how R&D has evolved from a focus on primary care to specialty medicine for rare disease as well as innovation in R&D sourcing models.
Click the PDF below to learn more.
IP Insights: Notable developments in IP litigation: April 2021
Sprint Communications Company LP v. WideOpenWest, Inc. et al., Case No. 1-18-cv-00361 (US District Court of Delaware) Sprint Communications filed lawsuits...